Rapid Antigen Tests Better at Identifying Symptomatic COVID-19 Cases, Finds Study
By LabMedica International staff writers Posted on 03 May 2021 |

Illustration
A review by an independent global network has shown that rapid antigen tests are better at correctly identifying cases of COVID-19 in people with symptoms than in people without symptoms.
The updated systematic review by Cochrane, a global independent network, along with leading experts at the University of Birmingham (Birmingham, UK), assessed rapid tests for the detection of SARS-CoV-2 infection (COVID-19). The review showed there are large differences in the accuracy of different brands of test, with very few meeting the World Health Organization (WHO) minimum acceptable performance standards.
Tests have been developed for diagnosing COVID-19 that can provide results ‘while you wait’. Two types of rapid ‘point of care’ tests are available, both of which use nose or throat samples. Antigen tests identify proteins on the virus and come in disposable plastic cassettes similar to pregnancy tests, with results available within 30 minutes. Molecular tests detect the virus’s genetic material, using desktop analyzers or small handheld devices with results typically available in 30 minutes to two hours. The Cochrane researchers wanted to know how accurate these tests are in determining infection in people with symptoms and in people without symptoms. They identified and summarized studies that measured the accuracy of any point-of-care tests used in hospitals or the community compared with the accepted standard laboratory test, RT-PCR, to detect current SARS-CoV-2 infection.
The first version of this review included 22 studies and was published in August 2020. The updated review now includes evidence from 64 studies. Most of the studies included in the review were from Europe and the US and assessed the accuracy of rapid antigen tests. Only three studies were exclusively in people without symptoms - two in people who were contacts of confirmed cases and one involved staff screening. Over half of the antigen test studies included samples from people being tested in the community, for example at test centers, emergency departments, or as part of contact tracing or outbreak investigations. Molecular test studies were mainly done in laboratories and not in the community where the tests were intended to be used.
The review authors found antigen tests were better at identifying COVID-19 in people with symptoms than they were in people without symptoms. In people with symptoms, on average 72% of people who had COVID-19 were correctly identified as being infected; tests performed best in the first week after symptoms began when they identified 78% of people who had COVID-19. In people without symptoms, on average, the antigen tests correctly identified 58% of those who were infected. Antigen tests correctly ruled out infection in 99.5% of uninfected people with COVID-19-like symptoms and 98.9% of uninfected people without symptoms. The percentage of people with COVID-19 who were correctly identified varied between brands and also depended on whether manufacturers’ instructions for using the tests were followed.
“Our review shows that some antigen tests may be useful in healthcare settings where COVID-19 is suspected in people with symptoms,” said Dr. Jac Dinnes, Senior Researcher in Public Health, Epidemiology and Biostatistics at the University of Birmingham. “These tests do not appear to perform as well in people who don’t have symptoms of COVID-19. Confirming a positive result from a rapid test with a RT-PCR test, particularly where cases of COVID-19 are low, may help avoid unnecessary quarantine.
“All antigen tests will miss some people with infection, so it is important to inform people who receive a negative test result that they may still be infected. There is some emerging evidence that the accuracy of the test is affected by who is doing it,” added Dr. Dinnes. “Future studies should look at the relationship between the experience of the person administering the test and the sensitivity of the test. Future research should also evaluate molecular tests in the settings in which they are intended to be used to clarify their performance in practice.”
Related Links:
University of Birmingham
The updated systematic review by Cochrane, a global independent network, along with leading experts at the University of Birmingham (Birmingham, UK), assessed rapid tests for the detection of SARS-CoV-2 infection (COVID-19). The review showed there are large differences in the accuracy of different brands of test, with very few meeting the World Health Organization (WHO) minimum acceptable performance standards.
Tests have been developed for diagnosing COVID-19 that can provide results ‘while you wait’. Two types of rapid ‘point of care’ tests are available, both of which use nose or throat samples. Antigen tests identify proteins on the virus and come in disposable plastic cassettes similar to pregnancy tests, with results available within 30 minutes. Molecular tests detect the virus’s genetic material, using desktop analyzers or small handheld devices with results typically available in 30 minutes to two hours. The Cochrane researchers wanted to know how accurate these tests are in determining infection in people with symptoms and in people without symptoms. They identified and summarized studies that measured the accuracy of any point-of-care tests used in hospitals or the community compared with the accepted standard laboratory test, RT-PCR, to detect current SARS-CoV-2 infection.
The first version of this review included 22 studies and was published in August 2020. The updated review now includes evidence from 64 studies. Most of the studies included in the review were from Europe and the US and assessed the accuracy of rapid antigen tests. Only three studies were exclusively in people without symptoms - two in people who were contacts of confirmed cases and one involved staff screening. Over half of the antigen test studies included samples from people being tested in the community, for example at test centers, emergency departments, or as part of contact tracing or outbreak investigations. Molecular test studies were mainly done in laboratories and not in the community where the tests were intended to be used.
The review authors found antigen tests were better at identifying COVID-19 in people with symptoms than they were in people without symptoms. In people with symptoms, on average 72% of people who had COVID-19 were correctly identified as being infected; tests performed best in the first week after symptoms began when they identified 78% of people who had COVID-19. In people without symptoms, on average, the antigen tests correctly identified 58% of those who were infected. Antigen tests correctly ruled out infection in 99.5% of uninfected people with COVID-19-like symptoms and 98.9% of uninfected people without symptoms. The percentage of people with COVID-19 who were correctly identified varied between brands and also depended on whether manufacturers’ instructions for using the tests were followed.
“Our review shows that some antigen tests may be useful in healthcare settings where COVID-19 is suspected in people with symptoms,” said Dr. Jac Dinnes, Senior Researcher in Public Health, Epidemiology and Biostatistics at the University of Birmingham. “These tests do not appear to perform as well in people who don’t have symptoms of COVID-19. Confirming a positive result from a rapid test with a RT-PCR test, particularly where cases of COVID-19 are low, may help avoid unnecessary quarantine.
“All antigen tests will miss some people with infection, so it is important to inform people who receive a negative test result that they may still be infected. There is some emerging evidence that the accuracy of the test is affected by who is doing it,” added Dr. Dinnes. “Future studies should look at the relationship between the experience of the person administering the test and the sensitivity of the test. Future research should also evaluate molecular tests in the settings in which they are intended to be used to clarify their performance in practice.”
Related Links:
University of Birmingham
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read more
Pen-Like Tool Quickly and Non-Invasively Detects Opioids from Skin
Opioid drugs such as fentanyl, morphine, and oxycodone are the primary substances associated with overdose cases in the United States. Standard drug screening procedures typically involve collecting blood,... Read moreMolecular Diagnostics
view channel
New Blood Test for Leukemia Risk Detection Could Replace Bone Marrow Sampling
Myelodysplastic syndrome (MDS) is a condition typically associated with aging, where blood stem cells fail to develop into fully functional blood cells. Early and accurate diagnosis is vital, as MDS can... Read more
Blood Test Detects Preeclampsia Risk Months Before Symptoms Appear
Preeclampsia, a pregnancy-related complication characterized by elevated blood pressure and organ dysfunction, remains a major contributor to maternal and infant health issues globally. Existing screening... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read moreMicrobiology
view channel
Credit Card-Sized Test Boosts TB Detection in HIV Hotspots
Current tuberculosis (TB) tests face major limitations when it comes to accurately diagnosing the infection in individuals living with HIV. HIV, a frequent co-infection with TB, complicates detection by... Read more
Fecal Metabolite Profiling Predicts Mortality in Critically Ill Patients
Critically ill patients in medical intensive care units (MICUs) often suffer from conditions such as acute respiratory distress syndrome (ARDS) or sepsis, which are linked to reduced diversity of gut microbiota... Read more
Portable Molecular POC System Rules Out UTIs in Just 35 Minutes
Urinary tract infections (UTIs) represent a massive burden on patients and healthcare systems. There are over 400 million UTI cases globally each year, of which around 90% are in women. Fast and accurate... Read more
POC Lateral Flow Test Detects Deadly Fungal Infection Faster Than Existing Techniques
Diagnosing mucormycosis—an aggressive and often deadly fungal infection—remains a major challenge due to the disease’s rapid progression and the lack of fast, accurate diagnostic tools. The problem became... Read morePathology
view channel
Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read more
Saliva-Based Testing to Enable Early Detection of Cancer, Heart Disease or Parkinson’s
Saliva is one of the most accessible biological fluids, yet it remains underutilized in clinical practice. While saliva samples are used to perform genetic tests to determine, for example, paternity, the... Read moreTechnology
view channel
New POC Biosensing Technology Improves Detection of Molecular Biomarkers
Traditional diagnostic procedures in medicine typically involve sending a patient’s blood or tissue samples to clinical laboratories, where trained scientists perform testing and data interpretation.... Read more
Enhanced Lab Data Management and AI Critical to Labs of the Future, Finds Survey
Data plays a key role in the transformation of today’s digital laboratories, acting both as a key challenge and a catalyst for innovation, as revealed by a survey of over 150 scientists.... Read moreIndustry
view channel
AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing
Homologous recombination deficiency (HRD) testing identifies tumors that are unable to effectively repair DNA damage through the homologous recombination repair pathway. This deficiency is often linked... Read more